Platform Lead Candidate
Chronic Wounds (Likely Diabetic Foot Ulcers)
PreclinicalActive R&D
Key Facts
Indication
Chronic Wounds (Likely Diabetic Foot Ulcers)
Phase
Preclinical
Status
Active R&D
Company
About Aethl Bio
Aethl Bio is a public, pre-revenue biotech (NASDAQ: ICOP) targeting the vast and underserved chronic wound market with a science-driven, function-focused approach. The company is building a platform and pipeline, as evidenced by its recent appointment of a Scientific Advisory Board expert in oxygen-based therapies, signaling a move into active development. Its strategy hinges on redefining therapeutic success from closure to durable, functional recovery, aiming to capture significant value in a market burdened by high costs and poor outcomes.
View full company profile